Siemens Atellica CH Triglycerides Reagent Causes Magnesium Test Errors
Siemens Healthcare recalls Atel:lica CH Triglycerides reagents that may cause inaccurate magnesium test results due to carryover from other tests.
Lower-risk recall
Reagent Carryover from LDL Cholesterol Direct (DLDL), Total Protein II (TP), Triglycerides (Trig), and Triglycerides_2 (Trig_2) Impacting Magnesium (Mg) Results
Contact the company
What happened, in plain English
Siemens Healthcare is recalling Atellica CH Triglycerides reagents used in blood tests. These reagents can cause inaccurate magnesium test results if used with certain other reagents. Read more at govinfonow.com/recall/58998-siemens-atellica-ch-triglycerides-reagent-causes-magnesium-test-errors.
Source Summary by GovInfoNow · govinfonow.com/recall/58998-siemens-atellica-ch-triglycerides-reagent-causes-magnesium-test-errors · Updated August 19, 2026 · FDA enforcement record: FDA #Z-1270-2023
Cite this page
“Siemens Atellica CH Triglycerides Reagent Causes Magnesium Test Errors.” GovInfoNow, updated August 19, 2026. https://govinfonow.com/recall/58998-siemens-atellica-ch-triglycerides-reagent-causes-magnesium-test-errors. Based on FDA recall #Z-1270-2023 (https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1270-2023%22&limit=1).
Why it’s dangerous
The reagents can carry over from other tests (LDL Cholesterol, Total Protein, Triglycerides) and interfere with magnesium measurements. This causes inaccurate test results for magnesium.
Who’s affected
Lab users who run blood tests with these reagents may be affected. People using the Atellica CH Analyzer system are most at risk.
How to tell if you have this one
Check for the Atellica CH Triglycerides reagents with the lot number 11097591 or UDI 00630414596495. These reagents are used in Siemens Atellica CH Analyzer systems.
- Brand
Siemens Healthcare- Category
Medical device
All 4 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Ongoing- Distribution
Nationwide Foreign: Country Albania Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile China Colombia Croatia Cura¿ao Czech Republic Denmark Ecuador Egypt Finland France Germany Greece Guadeloupe Hong Kong Hungary India Ireland Israel Italy Japan Kuwait Libya Malaysia Mexico Netherlands New Zealand Norway Oman Pakistan Paraguay Peru Philippines Poland Portugal Qatar Republic Korea Romania Saudi Arabia Serbia Singapore Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan, Province of China Thailand Ukraine United Arab Emirates United Kingdom Great Britain Uruguay Vatikancity Vietnam
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| Z-1268-2023 | Atellica CH LDL Cholesterol Direct (DLDL)-In vitro diagnostic quantitative determination of LDL cholesterol in human serum and plasma (lithium heparin) using the Atellica CH Analyzer. SMN: 11097632; UDI: 00630414596181 All Lots | 8420 units |
| Z-1269-2023 | Atellica CH Total Protein II- In vitro diagnostic use in the quantitative determination of total protein in human serum and plasma (lithium heparin) using the Atellica CH Analyzer. SMN: 11097604; UDI: 00630414596372 All Lots | 13071 units |
| Z-1270-2023 | Atellica CH Triglycerides (concentrated)-In vitro diagnostic use in the quantitative measurement of triglycerides in human serum and plasma (lithium heparin, potassium EDTA) using the Atellica CH Analyzer SMN: 11097591; UDI: 00630414596495 All Lots | 11824 units |
| Z-1271-2023 | Atellica CH Triglycerides_2: in vitro diagnostic use in the quantitative determination of triglycerides in human serum and plasma (lithium heparin, sodium heparin, potassium EDTA) using the Atellica CH Analyzer. SMN: 11537222; UDI: 00630414610955 All Lots | 5315 units |
What to do — step by step
Check Reagent Lot
Verify the lot number on the reagent container to confirm it is not 11097591 or UDI 00630414596495.
Where it went and when
Where it was distributed
Distributed nationwide, and outside the U.S.
FDA distribution: “Nationwide Foreign: Country Albania Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile China Colombia Croatia Cura¿ao Czech Republic Denmark Ecuador Egypt Finland France Germany Greece…” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide, and outside the U.S.
Recall timeline
FDA published this recall 7 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest medical device recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #Z-1270-2023 (January 27, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for Z-1270-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 19, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.